Clinical Activity of Pralatrexate in Patients with Cutaneous T-Cell Lymphoma Treated with Varying Doses of Pralatrexate

Publication date: Available online 27 June 2018Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Francine M. Foss, Terri L. Parker, Michael Girardi, Anlong LiSummaryCutaneous T-cell lymphomas (CTCL) are rare, heterogeneous non-Hodgkin lymphomas with poor prognoses. Treatment options for CTCL are limited by the their efficacy and tolerability profile. Pralatrexate has demonstrated efficacy in T-cell lymphomas, however dose-modifying adverse events, such as mucositis have occurred. We retrospectively reviewed clinical responses and toxicity in 27 CTCL patients treated with pralatrexate at doses ranging from 10-30mg/m2 and clinical response or disease stabilization was observed in 85% even at lower doses. Administration of leucovorin resulted in no change in the incidence of skin reactions in CTCL patients but reduced the incidence of mucositis.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research